Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010375 | 0.93 | JAK3 (0.56) | JAK3EGFRLCKCDK9ENPP2 | |
| SCHEMBL17021283 | 0.93 | JAK3 (0.55) | JAK3EGFRLCKNPY5RCDK9 | |
| SCHEMBL19010374 | 0.87 | JAK3 (0.48) | JAK3EGFRLCKENPP2EPHX2 | |
| SCHEMBL19010266 | 0.86 | MAPT (0.45) | JAK3NAMPTSTAT6 | |
| SCHEMBL17021280 | 0.85 | JAK3 (0.61) | JAK3EGFRLCKCDK9ENPP2 | |
| SCHEMBL2697667 | 0.83 | JAK3 (0.72) | JAK3EGFRLCKCDK9CCNT1 | |
| SCHEMBL17021383 | 0.80 | JAK3 (0.52) | JAK3EGFRLCKEPHX2BTK | |
| SCHEMBL19010268 | 0.79 | JAK3 (0.46) | JAK3STAT6 | |
| SCHEMBL17021316 | 0.79 | STAT6 (0.47) | JAK3STAT6 | |
| SCHEMBL19010260 | 0.78 | MAPT (0.54) | ENPP2STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK3 3/4885EGFR 1029/4885LCK 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.